Atlas Trials

A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

Clinical trial NCT01248364 · COMPLETED

Trial details

NCT number
NCT01248364
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 2
Start date
2010-11-01
Primary completion
2013-07-01
Enrollment
91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.